Near-term earnings trough but robust order intake
Company reported its 1H26 financial results, with revenue falling by 4.26% YoY to RMB2,573m and the bottom line down by 147% YoY to reach a net loss of RMB157m. The company’s robust 95.5% YoY growth in new orders provides good visibility into a multi-year growth cycle, driven by overseas renewable energy capacity expansion and AI data centre (AIDC) infrastructure opportunities. We slightly revise down 2026E EPS due to FX loss and maintain BUY rating.
Strong Overseas Renewables Energy Capacity Expansion Tailwind
Robust new order intake secures future revenue growth momentum. 1H26 new order surged by 95.5% YoY to reach a record high of RMB11,721m, which was primarily driven by the electronic chemicals segment, where new orders soared to RMB7,270m (1H25: RMB226M), mainly underpinned by strong overseas solar capacity build-out. The Chemical downstream orders rose 125% YoY to RMB292m, and O&G orders jumped 143%YoY to RMB947m, benefitting from the global FPSO (Floating Production Storage and Offloading) upcycle and ongoing Middle East reconstruction initiatives.
Medium-term outlook: Multi-phase solar and AIDC projects. Company has won a major solar upstream capacity build-out project in 1H26. Management is aiming to secure more projects and maintain a 5-year construction horizon. Furthermore, Morimatsu is actively expanding into global AI infrastructure supercycle, having successfully won two Southeast Asian AIDC projects with a top-tier global Cloud Service Providers (CSPs). We view this AIDC optionality as a potent valuation catalyst that has yet to be fully appreciated by the market.
1H26 results: Margin contraction drives net loss. Gross margin contracted by 7ppts to 22.4%, and net margin dropped 18.5ppts to -6.1%. The weak results were caused by 1) adverse FX movements. With an 81% overseas revenue contribution in 1H26, management is proactively mitigating currency risk by shifting to RMB settlements; 2) front-loaded SG&A expenses (+21.5% YoY) due to robust new order momentum; 3) RMB86m impairment provision related to existing projects; 4) deferred revenue recognition for an RMB200m project due to shipping delay.
Valuation
We cut our sales and earnings estimations by 2% and 13% respectively in 2026E, but revise up our 2027-28E sales forecast to factor in strong order intake. Our updated HK$10.9 TP is derived from a DCF methodology, which implies a 23x/16x 2026/27 P/E against 43%/24% YoY EPS growth in 2027/28.
我有话说